Pfizer Recalls Migraine Treatment
August 15, 2019 – Pfizer has announced a voluntary recall of two lots of Relpax® (eletriptan hydrobromide) 40mg tablets due to the potential presence of microorganisms belonging to genus Pseudomonas and genus Burkholderia. Relpax is indicated to provide acute treatment for migraines with or without aura in adults.
Lots AR5407 and CD4565 did not meet Pfizer’s in-house microbiological specifications, and there is a risk of infection if a patient consumes these products. In the general population, this risk is low. However, vulnerable patient populations (such as patients who have compromised immune systems), may be at risk of serious and potentially life-threatening infection. Pfizer had not received any reports of adverse events as of the date of the recall.
Pfizer asks individuals who have received free Relpax through its Patient Assistance Program (PAP) or Institutional Patient Assistance Program (IPAP) to check if their medication has come from the affected product lots. All other patients currently taking Relpax should check with the dispensing pharmacy to determine if their medication has been recalled and to arrange a return. Patients can also contact Stericycle at 877-225-9750 for assistance with returns. Adverse events that may be related to Relpax should be reported to the patient’s healthcare provider, and can also be reported to the U.S FDA’s MedWatch program.
For the full recall announcement, please visit the FDA’s website.
Benecard Central Fill dispensed a limited amount of the recalled product, and has contacted the affected members.